• 1
    Panzram G. Mortality and survival in type 2 (non-insulin dependent) diabetes. Diabetologia 1987; 30:123 31.
  • 2
    Songer TJ, DeBerry K, LaPorte RE, Tuomilehto J. International comparisons of IDDM mortality. Diabetes Care 1992; 15 (Suppl. 1):15 21.
  • 3
    Colwell JA, Bingham SF, Abraira C, Anderson JW, Comstock JP, Kwaan HC, Nuttall F. Veterans Administration Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: II. Effects of aspirin and dipyridamole on atherosclerotic vascular disease rates. Diabetes Care 1986; 9:140 8.
  • 4
    Schafer AI. The hypercoagulable states. Ann Intern Med 1985; 102:814 8.
  • 5
    Frade LJG, De La Calle H, Alava I, Navarro JL, Creighton LJ, Gaffney PJ. Diabetes as a hypercoagulable state: its relationship with fibrin fragments and vascular damage. Thromb Res 1987; 47:533 40.
  • 6
    Colwell JA & Halushka PV. Platelet function in diabetes. Br J Haematol 1980; 44:521 6.
  • 7
    Abrams CHS, Ellison N, Budzynski AZ, Shattil SJ. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 1990; 75:128 8.
  • 8
    Tschope D, Esser J, Schwippert B, Rosen P, Kehrel B, Nieuwenhuis HK, Gries FA. Large platelets circulate in an activated state in diabetes. Semin Thromb Haemost 1991; 17:433 9.
  • 9
    George JN, Thoi LL, McManus LM, Reimann TA. Isolation of human platelet membrane microparticles from plasma and serum. Blood 1982; 60:834 40.
  • 10
    Sims PJ, Faioni EM, Wiedmer T, Shattil SJ. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem 1988; 263:18205 12.
  • 11
    Nomura S, Komiyama Y, Miyake T et al. Amyloid β-protein precursor-rich platelet microparticles in thrombotic disease. Thromb Haemost 1994; 72:519 22.
  • 12
    Nomura S, Suzuki M, Katsura K et al. Platelet-derived microparticles may influence the development of atherosclerosis in diabetes. Atherosclerosis 1995; 116:235 40.DOI: 10.1016/0021-9150(95)05551-7
  • 13
    Cominacini L, Pasini AF, Garbin U et al. Elevated levels of soluble E-selectin in patients with IDDM and NIDDM: relation to metabolic control. Diabetologia 1995; 38:1122 4.DOI: 10.1007/s001250050401
  • 14
    Fries JWU, Williams AJ, Atkins RC, Newman W, Lipscomb MF, Collins T. Expression of VCAM-1 and E-selectin in an in vivo model of endothelial activation. Am J Pathol 1993; 143:725 37.
  • 15
    Davies MJ, Gordon JL, Gearing AJH, Pigott R, Woolf N, Katz D, Kyriakopoulos A. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM-1, and E-selectin in human atheroscrelosis. J Pathol 1993; 171:223 9.
  • 16
    Steiner M, Reinhardt KM, Krammer B, Ernst B, Blann AD. Increased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes are independent of glycaemic control. Thromb Haemost 1994; 72:979 84.
  • 17
    Cattell V. Macrophages in acute glomerular inflammation. Kidney Int 1994; 45:945 52.
  • 18
    Furuta T, Saito T, Ootaka T, Soma J, Obara K, Abe K, Yoshinaga K. The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis 1993; 21:480 5.
  • 19
    Rollins BJ, Yoshimura T, Leonard EJ, Prober SJ. Cytokine-activated human endothelial cells synthesize and secrete a monochemoattractant, MCP-1/JE. Am J Pathol 1990; 136:1229 33.
  • 20
    Colotta F, Borre A, Wang JM, Tattanelli M, Maddalena F, Polentarutti N, Peri G, Matovani A. Expression of a monocyte chemotactic cytokine by human mononuclear phagocytes. J Immunol 1992; 148:760 5.
  • 21
    Ihm CG, Park JK, Hong SP, Lee TW, Cho BS, Kim MJ, Cha DR, Ha H. A high glucose concentration stimulates the expression of monocyte chemotactic peptide 1 in human mesangial cells. Nephron 1998; 79: 33 37.
  • 22
    Baggiolini M, Dewald B, Moster B. Interleukin-8 and related chemotactic cytokines—CXC and CC chemokine. Adv Immunol 1994; 55:97 179.
  • 23
    Kameyoshi Y, Dorschner A, Mallet AI, Christophers E, Schroder JM. Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med 1992; 176:587 92.
  • 24
    Nomura S, Suzuki M, Kido H et al. Differences between platelet and microparticle glycoprotein IIb/IIIa. Cytometry 1992; 13:621 9.
  • 25
    Miyake T, Nomura S, Komiyama Y et al. Effect of a new monoclonal anti-glycoprotein IX antibody, KMP-9, on high shear-induced platelet aggregation. Thromb Haemost 1997; 78:902 9.
  • 26
    Nomura S, Nagata H, Oda K, Kokawa T, Yasunaga K. Effects of EDTA on membrane glycoprotein IIb-IIIa complex: analysis using flow cytometry. Thromb Res 1987; 47:47 58.
  • 27
    Yanabu M, Ozaki Y, Nomura S et al. Tyrosine phosphorylation and p72syk activation by an anti-glycoprotein Ib monoclonal antibody. Blood 1997; 89:1590 8.
  • 28
    Winocour PD. Platelet abnormalities in diabetes. Diabetes 1992; 41 (Suppl.):26 31.
  • 29
    Packham MA & Mustard JF. The role of platelets in the development and complications of atherosclerosis. Semin Hematol 1986; 23:8 19.
  • 30
    Tschope D, Spangenberg P, Esser J, Schwippert B, Kehrel B, Rosen P, Gries FA. Flow cytometric detection of surface membrane alterations and concomitant changes in the cytoskeletal actins status of activated platelets. Cytometry 1990; 11:652 6.
  • 31
    Murakami T, Komiyama Y, Masuda M et al. Flow cytometric analysis of platelet activation markers CD62P and CD63 in patients with coronary artery disease. Eur J Clin Invest 1996; 26:996 1003.
  • 32
    Koch AE, Kunkel SL, Harlow LA, Mazarakis DD, Haines GK, Burdick MD, Pope RM, Stieter RM. Macrophage inflammatory protein-1: a novel chemokine cytokine for macrophages in rheumatoid arthritis. J Clin Invest 1994; 93:921 8.
  • 33
    Pattison J, Nelson PJ, Huie P, Von Leuttichau I, Farshid G, Sibley RK, Krensky AM. RANTES chemokine expression in cell-mediated transplant rejection of the kidney. Lancet 1994; 343:209 11.
  • 34
    Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1α, and MIP-1β as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995; 270:1811 5.
  • 35
    Holme PA, Muller F, Solum NO, Brosstad F, Froland SS, Aukrust P. Enhanced activation of platelets with abnormal release of RANTES in HIV-1 infection. FASEB J 1998; 12:79 90.
  • 36
    Weyrich AS, Elstad MR, McEver RP, McIntyre TM, Moore KL, Morrissey JH, Prescott SM, Zimmerman GA. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest 1996; 97:1525 34.
  • 37
    Neumann F-J, Marx N, Gawaz M et al. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation 1997; 95:2387 94.
  • 38
    Gent M. A systematic overview of randomized trials of antiplatelet agents for the prevention of stroke, myocardial infarction, and vascular death. In: HassWK, EastonJD, eds. Ticlopidine, platelets and vascular disease. New York: Springer-Verlag, 1993: 99 116.
  • 39
    Report of a WHO Study Group. Diabetes. Tech Rep Series 1985; 727:58 67.
  • 40
    Graier WF, Wascher TC, Lackner L, Toplak H, Krejs GJ, Kukovetz WR. Exposure to elevated d-glucose concentrations modulates vascular endothelial cell vasodilatory response . Diabetes 1993; 42: 1497 505.
  • 41
    Miyazaki Y, Nomura S, Miyake T et al. High shear stress can initiate both platelet aggregation and shedding of procoagulant containing microparticles. Blood 1996; 88:3456 64.
  • 42
    Venturini CM & Kaplan JE. Thrombin induces platelet adhesion to endothelial cells. Semin Thromb Hemost 1992; 18:275 83.
  • 43
    Springer TA. Adhesion receptors of the immune system. Nature 1990; 346:425 34.
  • 44
    Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Ann Rev Immunol 1993; 1:767 804.
  • 45
    Shimano H, Takahashi K, Kawakami M, Gotoda T, Harada K, Shimada M, Yazaki Y, Yamada N. Elevated serum and urinary thrombomodulin levels in patients with non-insulin-dependent diabetes. Clin Chim Acta 1994; 225:89 96.
  • 46
    Barcellini W, Borghi MO, Lazzaroni E, Vismara A, Ferraro G, Meroni PL. Study on the interference of ticlopidine on the immune system. Int J Tiss Reac 1988; 10:183 8.
  • 47
    May AE, Neumann F-J, Gawaz M, Ott I, Walter H, Schomig A. Reduction of monocyte–platelet interaction and monocyte activation in patients receiving antiplatelet therapy after coronary stent implantation. Eur Heart J 1997; 18:1913 20.